The FDA has removed black box warnings on estrogen treatments for menopause, igniting a debate about the benefits and risks of hormone therapy. Dr. Marty Makary discusses the implications for women's health.
Isabel Kallman grapples with perimenopause symptoms and the decision to consider hormone therapy. Experts argue that the risks associated with treatment may have been overstated, calling for a reevaluation of FDA warnings.
Doctors are pushing the FDA to remove black box warnings on low-dose estrogen treatments, arguing it discourages women from beneficial hormone therapies for menopause. Experts claim the risks are overstated and can hinder treatment.